Vestal Point Capital, LP Cytokinetics Inc Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
A detailed history of Vestal Point Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,350,000 shares of CYTK stock, worth $101 Million. This represents 6.55% of its overall portfolio holdings.
Number of Shares
2,350,000
Previous 1,500,000
56.67%
Holding current value
$101 Million
Previous $79.2 Billion
39.58%
% of portfolio
6.55%
Previous 6.01%
Shares
5 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
115MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$629 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$510 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$461 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$264 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$122 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.03B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...